Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
CEL-SCI is a biotechnology business based in the US. CEL-SCI shares (CVM) are listed on the NYSE MKT and all prices are listed in US Dollars.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $2.24 |
|---|---|
| 52-week range | $1.88 - $5.42 |
| 50-day moving average | $2.69 |
| 200-day moving average | $3.34 |
| Wall St. target price | $10.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.84 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.24 from 2023-03-20
| 1 week (2023-03-14) | -8.94% |
|---|---|
| 1 month (2023-02-21) | -22.49% |
| 3 months (2022-12-21) | 8.21% |
| 6 months (2022-09-21) | -35.82% |
| 1 year (2022-03-21) | -48.51% |
|---|---|
| 2 years (2021-03-19) | -87.34% |
| 3 years (2020-03-20) | 11.95 |
| 5 years (2018-03-21) | 45.45% |
| Revenue TTM | $28,558 |
|---|---|
| Gross profit TTM | $-25,355,346 |
| Return on assets TTM | -38.16% |
| Return on equity TTM | -94.61% |
| Profit margin | 0% |
| Book value | $0.61 |
| Market capitalisation | $101.5 million |
TTM: trailing 12 months
We're not expecting CEL-SCI to pay a dividend over the next 12 months.
CEL-SCI's shares were split on a 1:25 basis on 14 June 2017. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI shares which in turn could have impacted CEL-SCI's share price.
Over the last 12 months, CEL-SCI's shares have ranged in value from as little as $1.88 up to $5.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI's is 1.7127. This would suggest that CEL-SCI's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 product candidates for the treatment of rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. .
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.